KRAS-siRNA therapy (Washington University in St Louis/University of South Florida)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameKRAS-siRNA therapy (Washington University in St Louis/University of South Florida)

Drug Alias NameN/A

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisenseBiologics > Protein drugs > Recombinant polypeptideSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA

Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitors

TargetsGTPase KRas

Therapy Area/IndicationsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesWashington University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesWashington University University Of South Florida

Active IndicationsN/A

Inactive IndicationsPancreatic Neoplasms

Other Information

ATC CodeN/A